Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population‐based cohort
Journal of Cachexia, Sarcopenia and Muscle · 2024-08 · 15 (4) · 1528-1538
DOI: 10.1002/jcsm.13511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 19.06.2024. Verfasst von Dion Groothof und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Biomarkers, Creatinine, Cystatin C. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Serum creatinine is used as initial test to derive eGFR and confirmatory testing with serum cystatin C is recommended when creatinine‐based eGFR is considered less accurate due to deviant muscle mass. Low muscle mass is associated with increased risk of premature mortality. However, the associations of serum creatinine and cystatin C with muscle mass and mortality remain unclear and require further investigation to better inform clinical decision‐making.
Methods
We included 8437 community‐dwelling adults enrolled in the Dutch PREVEND study and 5033 in the US NHANES replication cohort. Associations of serum creatinine and/or cystatin C with muscle mass surrogates and mortality were quantified with linear and Cox proportional hazards regression, respectively. Missing observations in covariates were multiply imputed using Substantive Model Compatible Fully Conditional Specification.
Results
Mean (SD) age of PREVEND and NHANES participants (50% and 48% male) were 49.8 (12.6) and 48.7 (18.7) years, respectively. Median (Q1–Q3) serum creatinine and cystatin C were 71 (61–80) and 80 (62–88) μmol/L and 0.87 (0.78–0.98) and 0.91 (0.80–1.10) mg/L, respectively. Higher serum creatinine was associated with greater muscle mass, while serum cystatin C was not associated with muscle mass. Adjusting both markers for each other strengthened the positive relationship between serum creatinine and muscle mass and revealed an inverse association between serum cystatin C and muscle mass. In the PREVEND cohort, 1636 (19%) deaths were registered over a median follow‐up of 12.9 (5.8–16.3) years with a 10‐year mortality rate (95% CI) of 7.6% (7.1–8.2%). In the NHANES, 1273 (25%) deaths were registered over a median follow‐up of 17.9 (17.3–18.5) years with a 10‐year mortality rate of 13.8% (12.8–14.7%). Both markers were associated with increased mortality. Notably, when adjusted for each other, higher serum creatinine was associated with decreased mortality, while the association between serum cystatin C and increased mortality strengthened. The shapes of the associations in the PREVEND study and NHANES were almost identical.
Conclusions
The strong association between serum creatinine and muscle mass challenges its reliability as GFR marker, necessitating a more cautious approach in its clinical use. The minimal association between serum cystatin C and muscle mass supports its increased use as a more reliable alternative in routine clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Biostatistics, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, the Netherlands.
- Department of Epidemiology, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, the Netherlands.
- Department of Internal Medicine, Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, the Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Surgery, Division of Vascular and Transplantation Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Dion Groothof, Naser B N Shehab, Nicole S Erler, Adrian Post, Daan Kremer, Harmke A Polinder-Bos, Ron T Gansevoort, Henk Groen, Robert A Pol, Reinold O B Gans, Stephan J L Bakker
Zitieren
APA
Groothof, D., Shehab, N. B. N., Erler, N. S., Post, A., Kremer, D., Polinder-Bos, H. A., Gansevoort, R. T., Groen, H., Pol, R. A., Gans, R. O. B., & Bakker, S. J. L. (2024). Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population‐based cohort. Journal of Cachexia, Sarcopenia and Muscle, 15(4), 1528-1538. https://doi.org/10.1002/jcsm.13511
Vancouver
Groothof D, Shehab NBN, Erler NS, Post A, Kremer D, Polinder-Bos HA, et al. Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population‐based cohort. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(4):1528-1538. doi:10.1002/jcsm.13511
BibTeX
@article{Groothof2024,
author = {Groothof, Dion and Shehab, Naser B N and Erler, Nicole S and Post, Adrian and Kremer, Daan and Polinder-Bos, Harmke A and Gansevoort, Ron T and Groen, Henk and Pol, Robert A and Gans, Reinold O B and Bakker, Stephan J L},
title = {Creatinine, cystatin C, muscle mass, and mortality: Findings from a primary and replication population‐based cohort},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
volume = {15},
number = {4},
pages = {1528--1538},
doi = {10.1002/jcsm.13511}
}
EUVIMED